News Release


May 22,2025
ExaWizards Inc.
(TSE Code No.4259)
ExaMD Inc.

ExaMD, a Member of the ExaWizards Group, Launches a Gait Analysis AI Application for Medical Institutions

— Simplifying Gait Function Visualization with a Smartphone,
Collaborative Development with Juntendo University —

ExaMD Inc. (Minato-ku, Tokyo, Representative Director: Koji Hazama; hereinafter, “ExaMD”), a member of the ExaWizards Group, is pleased to announce the development of a medical AI application that analyzes patients' gait functions with artificial intelligence (AI), scheduled for launch in Q2 2025. In connection with this initiative, ExaMD signed a collaborative development agreement with Juntendo University in May 2025. The collaboration will establish medical evaluations, build clinical evidence, and ensure the safety of the product as a medical device.

ExaMD is committed to addressing the challenges of a super-aging society by leveraging AI, particularly in the fields of "musculoskeletal/rehabilitation" and "dementia" that are designated for priority review by regulatory authorities. ExaMD acquired a license for the manufacture and sales of medical devices in March 2025, allowing the company to develop and distribute medical devices.



☑Background

As societies age, issues in gait function caused by fractures and joint- or musculoskeletal-related disorders significantly impact daily living and quality of life.
Existing gait analysis tools often require specialized equipment, large spaces for installation, trained operators, and long wait times for diagnostic results.
In response to these challenges, ExaMD has developed a medical AI application for gait analysis for smartphones. Healthcare providers can analyze videos of a patient walking captured on a

smartphone, allowing for instant gait function visualization. The app supports early issue detection, allowing elderly individuals to understand their physical condition and prolong their healthy lifespan.

☑Key Features of the AI Gait Analysis App

✓ User-Friendly Interface

The app operates on standard devices such as smartphones and tablets, offering intuitive usability without requiring specialized knowledge.

✓ Rapid Diagnostic Support

The AI can analyze a patient's gait during a five-meter walk in as little as 5 seconds. Metrics such as "walking speed," "stability," "left-right asymmetry," and "tempo" are scored and presented in a clear, easy-to-understand format.

✓ Visualization of Longitudinal Changes

The app allows comparison with past data. Histograms and a comparison feature with previous videos allow tracking and understanding of changes in a patient's gait over time.

✓ Report Generation

The app can generate reports on motion analysis (D250), which is eligible for insurance reimbursement.

☑Product Availability

The AI gait analysis application will be provided by ExaMD, who holds a medical device manufacturing and sales license. The product is scheduled for release in Q2 2025 (July–September).

☑Collaboration with Juntendo University

This collaborative effort involved Professor Takashi Tamura from the Graduate School of Medicine, Sports Medicine Sportology/ Metabolic and Endocrine Medicine, Juntendo University.
The primary goals of the app are to include medical evaluations, building clinical evidence, and ensure the safety of the app as a medical device. Integrating Juntendo University's extensive knowledge from long-term cohort studies on the relationship between exercise habits and health risks with ExaMD's expertise in developing new digital health services using AI biomarkers will allow the two parties to create a groundbreaking AI application for gait function evaluation.

(Note: AI biomarkers refer to systems that use data obtained from digital devices and AI to visualize health conditions and outcomes.)

☑About ExaMD

ExaMD was established in February 2024 to provide Software as a Medical Device (SaMD). It is a 100% subsidiary of ExaWizards, an AI development company.
ExaMD is addressing two major social challenges faced by super-aging societies: "musculoskeletal/rehabilitation" and "dementia." The company's AI medical device for dementia was designated as a priority review candidate under the Innovative Program for Medical Devices by Japan's Ministry of Health, Labour and Welfare in February 2025.*1
In March 2025, ExaMD acquired licenses for the manufacture and sales of Class II medical devices, allowing the company to manage all aspects of SaMD development, manufacturing, and distribution.*2

In the future, ExaMD will form alliances with healthcare, IT, research, sales, and service partners to accelerate the practical application of SaMD in medical institutions. ExaMD also envisions working with a wide range of partners to implement solutions in both B2B and B2B2C settings for broader societal impact.
For further details, please visit ExaMD's website: https://examd.com/

*1 ExaMD Press Release https://exawizards.com/en/archives/29491/
*2 ExaMD Press Release https://exawizards.com/en/archives/29863/

【ExaMD Company Profile】
Company name: ExaMD Inc.
Location: 4-2-8 Shibaura, Minato-ku, Tokyo, 5F
Established: February 2024
Representative: Koji Hazama, Representative Director
Business: Planning, development, sales, and alliance of products and services using multi-modal AI technology to solve social issues related to healthcare
URL: https://examd.com/

【ExaWizards Corporate profile】
Company name: ExaWizards Inc
Location: 4-2-8 Shibaura, Minato-ku, Tokyo, 5F
Established: February 2016
Representative: Makoto Haruta, Representative Director & President CEO
Business: Industrial innovation and resolution of social issues via AI service development
URL: https://exawizards.com/en/

<Media Contact>
ExaWizards Inc. Public Relations: publicrelations@exwzd.com